Advertising

Case study
Volume 54, Issue 11, November 2025

Breaking out: The wild world of diagnosing and managing drug eruptions

Jessica Lee    John Sullivan    Joseph Joseph   
doi: 10.31128/AJGP-12-24-7506   |    Download article
Cite this article    BIBTEX    REFER    RIS

CASE

A man, aged 52 years, presented to the emergency department with a first-time presentation of sudden onset pruritic skin eruption after starting allopurinol 10 days prior for nephrolithiasis. He reported mild shortness of breath but no other significant systemic symptoms. The pruritic eruption was symmetrical, widespread with erythematous macules and papules involving his face, torso and limbs (Figure 1). He had slight facial swelling, was febrile to 38.3°C and had mild tachycardia (112 beats/min), but was otherwise haemodynamically stable. He was treated with a three-day course of 25 mg prednisone.


Figure 1. Initial presentation of the eruption on the patient’s trunk. (A) Eruption on the chest wall and abdomen anteriorly. (B) Eruption on the back.
Figure 1. Initial presentation of the eruption on the patient’s trunk. (a) Eruption on the chest wall and abdomen anteriorly. (b) Eruption on the back.
Question 1

What are the differential diagnoses?

Question 2

What history, examination and investigations are required?

Answer 1

The main differential diagnosis is morbilliform drug reaction. An important differential is an early evolving drug hypersensitivity syndrome known as drug reaction with eosinophilia and systemic symptoms (DRESS) given pruritic skin eruptions and organ involvement commonly associated with allopurinol.1 Other differentials include infection-associated exanthematous drug eruption, drug-induced exanthematous eruptions or acute viral illness (eg measles, acute HIV).

Less common differentials include early Stevens–Johnson syndrome or toxic epidermal necrolysis (SJS/TEN), acute generalised exanthematous pustulosis (AGEP) and acute cutaneous lupus. The timing of drug exposure supports morbilliform drug eruption, with high fever suggesting systemic involvement or impending SJS/TEN.

Answer 2

Table 1 outlines important factors for history, examination and investigations.

Table 1. Important characteristics in history, examination and investigations for diagnosing and managing drug reactions
  Characteristics
History
  • Drug exposure – Has the patient had the medication previously?
  • Timing – How long has the patient been taking the medication for? What is the timing of drug administration relative to the onset of rash and other symptoms?
  • Adherence – Has the patient been taking the medication as prescribed?
  • Complete medication and medical history with collateral information from the pharmacy including herbs, eye drops and vitamins
  • Medical history – Immunocompromised? Recent viral illnesses and viral symptoms? Vaccination history?
  • Social history – Infectious contacts and travel history
  • Skin pain
  • Systems review – Fevers, night sweats, weight loss, headache, vomiting, chest pain, shortness of breath, joint pain, nausea, abdominal pain, diarrhoea
Examination
  • Vital signs
  • Lymph node examination – Are there palpable lymph nodes? Lymph nodes >2 cm are suggestive of DRESS
  • Mucous membrane examination – Are there any lesions or active bleeding in the gums or other mucosal areas?
  • Full skin examination looking for confluent erythema, facial oedema, blisters, erosions, necrosis and purpura
  • Cardiovascular and respiratory examinations – Are there any signs of infection, respiratory distress/pneumonia?
Investigations
  • Assess for systemic involvement based on symptoms and presentation; some potential investigations include:
    • Full blood count – Leucocytosis (>11 × 103/μL), atypical lymphocytosis (>5%) or eosinophilia (>1.5 × 103/μL) suggestive of DRESS
    • Liver function tests – Elevated LFTs (liver transaminases values > twice the upper normal limit) suggestive of DRESS
    • Electrolyte, urea and creatine tests – Abnormal LFTs indicating interstitial nephritis suggestive of DRESS
    • Troponin – Elevated troponin indicating carditis suggestive of DRESS
DRESS, drug reaction with eosinophilia and systemic symptoms; LFTs, liver function tests.

Case continued

After admission, the eruption became more confluent and erythematous with dusky targetoid areas (Figure 2). There was no skin tenderness, detachment or mucosal involvement. Eosinophils, lymphocytes, liver function, renal function and troponin were normal. No new systemic features such as worsening fever, hypotension or lymphadenopathy were noted. The presently accepted diagnostic tool RegiSCAR (diagnostic scoring criteria used to assist in diagnosing DRESS) score assisted in confirming diagnosis (Box 1).1


Figure 2. Progression of eruption on the patient’s trunk. (A) Progression of the eruption on the chest wall and abdomen. (B) Progression of the eruption on the back with arrows indicating dusky targetoid areas.

Figure 2. Progression of eruption on the patient’s trunk. (a) Progression of the eruption on the chest wall and abdomen. (b) Progression of the eruption on the back with arrows indicating dusky targetoid areas.


Box 1. RegiSCAR (diagnostic scoring tool) criteria for the diagnosis of DRESS
Criteria for diagnosis
  • Acute rash
  • Reaction suspected to be drug-related
  • Hospitalisation
  • Fever (>38°C)
  • Laboratory abnormalities
    (at least one present)
    • Lymphocyte above or below
      normal level
    • Low platelet level
    • Eosinophilia
  • Involvement of more than one
    internal organ
  • Enlarged lymph nodes present at more than two sites
The first three criteria are necessary for diagnosis, along with the presence of three out of the other four features listed.1
DRESS, drug reaction with eosinophilia and systemic symptoms.
Question 3

Why is morbilliform drug eruption diagnosed over DRESS?

Question 4

How common are allopurinol-induced skin eruptions?

Question 5

Which common drugs cause adverse cutaneous reactions?

Question 6

What is the definitive management?

Answer 3

DRESS must be excluded as it has high morbidity and a 10% mortality.2 Typically, DRESS presents with high fever and lymphadenopathy with neutrophilia in early presentation, followed by lymphopenia and eosinophilia as the condition resolves (Table 2).3,4 Lack of lymphadenopathy, other organ involvement and normal blood tests support morbilliform drug eruption.

Table 2. Clinical features of SJS/TEN, DRESS and exanthematous drug reactions
Clinical features SJS/TEN DRESS Exanthematous drug reactions
Cutaneous features Severe blistering, Nikolsky sign positive with significant epidermal necrosis (10–30% TBSA affected is SJS, >30% TBSA is TEN) Widespread rash (>50% TBSA) with erythroderma, purpuric eruptions Widespread, symmetrically distributed rash composed of pink-to-red macules and papules that might coalesce to form plaques
Mucosal involvement Mucosal involvement highly frequent Mucosal involvement infrequent Mucosal involvement rare
Timing 4–21 days after first dose of medication >14 days after first dose of medication 4–21 days after first dose of medication
Systemic features High fever (>38.5°C)
Malaise, sore throat, dysphagia, dysuria or photophobia initially
High fever (>38.5°C)
Malaise, lymphadenopathy, involvement of at least one internal organ
Mild fever, malaise, sore throat and conjunctivitis
Laboratory findings Epidermal necrosis on skin biopsy, with full thickness loss of epidermis Eosinophilia, lymphocytosis or lymphopenia, atypical lymphocytes, thrombocytopenia Blood investigations typically at patient baseline
DRESS, drug reaction with eosinophilia and systemic symptoms; SJS/TEN, Stevens–Johnson syndrome or toxic epidermal necrolysis; TBSA, total body surface area.
Answer 4

Allopurinol is commonly used to treat gout and nephrolithias.5 The incidence of allopurinol causing severe cutaneous adverse reactions (SCARs) requiring hospitalisation is less than 1 in 1000, with in-hospital mortality as high as 27%.5 Certain groups, including those with kidney disease or those taking thiazide diuretics, are more susceptible to reactions.4,6 Southeast Asian ethnicities, such as Han Chinese, Indians and Koreans, should undergo HLA-B5801 screening before starting allopurinol, as this allele is strongly linked to severe reactions.7 Given the high percentage of Chinese ancestry in Australian regions like Sydney (29%), this is especially relevant for drug-related skin eruptions in clinical practice.8 Although our Caucasian patient was not eligible for HLA testing, patients should be informed of the risks with allopurinol and seek medical care if skin reactions occur.

Answer 5

Common drugs causing adverse cutaneous reactions are:4,6

  • allopurinol (3.75%)
  • anticonvulsants containing aromatic rings (eg lamotrigine, carbamazepine, phenytoin and phenobarbituates; 33%)
  • antibiotics (eg penicillins, cephalosporins, trimethoprim-sulfamethoxazole, minocycline, dapsone, vancomycin; 34%)
  • non-steroidal anti-inflammatories (22%).
Answer 6

The offending medication should be promptly ceased and not rechallenged. For pruritus relief, antihistamines, cool creams and showers with gentle patting are recommended. Topical therapy includes emollients and steroid creams for severe cases.4,6 Wet dressings for very erythematous and inflamed skin assist with symptom relief. Systemic corticosteroids (0.5–1 mg/kg) are reserved for severe cases with suspected DRESS or significant systemic involvement as they cause side effects like mania, hypertension and hyperglycaemia, causing more harm than benefit if used for mild drug reactions.2 Isolated exanthems improve in two weeks, whereas DRESS might take 6–12 weeks or longer for full recovery.9,10


Case continued

The patient developed no new systemic symptoms, and blood tests remained normal. He was managed conservatively with topical steroids (methylprednisolone 0.1% fatty ointment), loratadine 10 mg when needed, cooled emollients and cool showers. He was discharged, and the eruption resolved without issue on follow-up.


Key points

  • DRESS is a potentially life-threatening drug reaction with high morbidity and mortality; absence of systemic symptoms and normal blood tests suggests an exanthematous eruption.
  • Discontinue the offending medication immediately, where symptom management involves topical treatments like emollients and steroid creams.
  • Allopurinol can cause severe reactions, especially in patients from ethnic groups like Han Chinese, Indian or Korean who should be screened for HLA-B5801 and should be aware of SCARs, seeking medical care if needed.
Competing interests: None.
Provenance and peer review: Not commissioned, externally peer reviewed.
Funding: None.
Correspondence to:
jessica.lee8371@gmail.com
This event attracts CPD points and can be self recorded

Did you know you can now log your CPD with a click of a button?

Create Quick log
References
  1. Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergol Int 2019;68(3):301–08. doi: 10.1016/j.alit.2019.03.006. Search PubMed
  2. Pathania V, Sinha A, Sood A, et al. DRESS, the maverick among SCARS: A case series-based review of literature. Med J Armed Forces India 2023;79(3):328–36. doi: 10.1016/j.mjafi.2020.11.027. Search PubMed
  3. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: A retrospective study of 60 cases. Arch Dermatol 2010;146(12):1373–79. doi: 10.1001/archdermatol.2010.198. Search PubMed
  4. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist? Br J Dermatol 2007;156(3):609–11. doi: 10.1111/j.1365-2133.2006.07704.x. Search PubMed
  5. Kim SC, Newcomb C, Margolis D, Roy J, Hennessy S. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: A population-based cohort study. Arthritis Care Res (Hoboken) 2013;65(4):578–84. doi: 10.1002/acr.21817. Search PubMed
  6. Ng WL, Lim KS, Hariraj V, et al. Incidence of allopurinol-induced severe cutaneous adverse drug reaction in Malaysia. Br J Clin Pharmacol 2022;88(8):3782–88. doi: 10.1111/bcp.15327. Search PubMed
  7. Tse T, Wu B, Vagholkar S, Willcock S. Allopurinol for gout: Consider the case for limited HLA-B*5801 screening. Aust J Gen Pract 2022;51(10):813–14. doi: 10.31128/AJGP-12-21-6264. Search PubMed
  8. Australian Bureau of Statistics (ABS). 2021 Census all persons quickStats. ABS, 2021. Available at www.abs.gov.au/census/find-census-data/quickstats/2021/AUS [Accessed 22 January 2025]. Search PubMed
  9. Rawlin M. Exanthems and drug reactions. Aust Fam Physician 2011;40(7):486–89. Search PubMed
  10. Calle AM, Aguirre N, Ardila JC, Cardona Villa R. DRESS syndrome: A literature review and treatment algorithm. World Allergy Organ J 2023;16(3):100673. doi: 10.1016/j.waojou.2022.100673. Search PubMed

Skin diseasesTherapeutics

Download article